logo
Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients

Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients

Business Wire09-05-2025

BOSTON--(BUSINESS WIRE)--A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries.
Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting—seven saw an increase in patient out-of-pocket costs.
Share
The IRA Medicare Drug Access Tracker, developed by Dr. William Smith and Dr. Robert Popovian, monitors the impact of the Inflation Reduction Act's (IRA) drug pricing provisions. Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting— seven saw an increase in patient out-of-pocket costs. (The insulin product was not studied since its price was fixed in statute under a separate IRA provision.)
'The price controls show that Congress fundamentally doesn't understand the rebate system that underpins the pharmaceutical market,' said Dr. William Smith, who built the Tracker with Dr. Robert Popovian. 'All the politicians who argued that the IRA law would make drugs more affordable should look at this new data.'
Under the current system, drug manufacturers pay substantial rebates to pharmacy benefit managers (PBMs) such as Caremark and Optum. These rebates help offset costs but are invisible to patients. When CMS seeks to control prices by lowering a drug's official 'list price,' as it does with the anti-coagulant Eliquis —bringing the price down from $521 to $231—rebates disappear, likely eliminating hundreds of millions in rebate payments from manufacturers to PBMs. PBMs appear to be compensating for that loss by raising co-pays, co-insurance, and transferring other charges directly to patients.
The IRA Medicare Drug Access Tracker focuses on Medicare patients served by the four largest PBMs, which account for 87 percent of the market. The tool is designed to measure whether federal price controls actually improve affordability for seniors by tracking out-of-pocket costs over time. It also follows administrative burdens that PBMs may have imposed on these drugs, which may strain already short-staffed providers, such as requiring them to fill out additional paperwork to secure a prescription (prior authorization) or placing quantity limits on the medications. Such administrative burdens are often used in the industry to discourage demand (demand management).
Among the Tracker's key findings:
Average out-of-pocket costs for the nine drugs rose 32 percent, from $74.51 to $98.42
Seven of the nine drugs saw individual cost increases ranging from $10.56 to $316.81
One of the two medicines seeing no increase in out-of-pocket costs faced competition from biosimilars that only became available in 2025
'Higher out-of-pocket costs are unlikely to be the only unintended consequence of drug price controls,' Dr. Popovian said. 'The IRA also creates less incentive for pharmaceutical innovation and increases the possibility that some popular drugs may be excluded from health insurance formularies.'
This release marks the Tracker's first report. Pioneer Institute will publish additional data later this year, as more drugs fall under the Inflation Reduction Act's price-setting provisions.
The public can find the tool at https://pioneerinstitute.org/rxpricewatch/
Dr. William S. Smith is Senior Fellow & Director of Pioneer Life Sciences Initiative. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor's office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer's corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.
Dr. Robert Popovian is the Founder of the strategic consulting firm Conquest Advisors. He also serves as Chief Science Policy Officer at the Global Healthy Living Foundation, Senior Healthy Policy Fellow at the Progressive Policy Institute, and Visiting Health Policy Fellow at the Pioneer Institute. He previously served as Vice President, U.S. Government Relations at Pfizer.
One of the country's foremost experts on every significant facet of biopharmaceuticals and the healthcare industry, he is a recognized authority on health economics, policy, government relations, medical affairs, and strategic planning. To learn more about Dr. Popovian please click here.
About Pioneer Institute
Pioneer empowers Americans with choices and opportunities to live freely and thrive. Working with state policymakers, we use expert research, educational initiatives, legal action and coalition-building to advance human potential in four critical areas: K-12 Education, Health, Economic Opportunity, and American Civic Values.
Please see below the first group of drugs subject that Pioneer is studying.
Eliquis
Enbrel
Entresto
Farxiga
Imbruvica
Januvia
Jardiance
Stelara
Xarelto

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Spineology ® Announces the Launch of OptiMesh Align™
Spineology ® Announces the Launch of OptiMesh Align™

Business Wire

timean hour ago

  • Business Wire

Spineology ® Announces the Launch of OptiMesh Align™

ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology Inc., the pioneers of Conform and Expand™ Technology, today announced the launch of its latest innovation, and most advanced patient specific solution yet: OptiMesh Align™ (Align). Built on the proven foundation of OptiMesh ®, Align is uniquely engineered to provide real time, in-situ, independent anterior and posterior implant expansion resulting in a customized, patient specific lordotic shape up to 20 degrees. Align is delivered through one of the smallest insertion profiles available, expanding to one of the largest implant footprints, enabling correction not typically associated with minimally invasive posterior spine approaches. OptiMesh utilizes a biologics-based expansion method, which is designed to overcome limitations and reduce point-loading commonly seen with mechanically expandable implant technology. 'Sagittal alignment is widely considered one of the key correlative indicators to achieving long term clinical success for spine patients. The OptiMesh technology remains the only conforming expandable implant that offers a personalized solution for each patient,' said Brian Snider, Chief Executive Officer. 'With the addition of the lordotic capabilities of the Align implant, our portfolio provides more options to achieve the clinical requirements of surgery.' OptiMesh Align is engineered to produce distraction forces and endplate conformance, provide strength and stability to restore disc height, create a robust fusion scaffold, and now further supports the achievement of alignment objectives. This breakthrough is driven by Spineology's proprietary Conform and Expand flexible mesh interbody technology, setting a new standard for patient specific lumbar interbody fusion. About Spineology Spineology Inc. are the pioneers of Conform and Expand™ technology, a novel development method used in the design of spinal expandable implants. Spineology's core portfolio, OptiMesh ® is the only conforming patient specific spinal implant on the market. OptiMesh is backed with IDE level data which further sets the company apart from traditional fusion procedures. OptiMesh is designed to enable surgeons to support outcomes, and patient recovery while minimizing tissue disruption. With a strong commitment to patient-centered care, Spineology aspires to provide every spine patient the freedom from pain through the creation and delivery of ultra-MIS solutions. For more information about Spineology, visit and follow us on LinkedIn, or Twitter.

Nearly Three in Four Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Instead of Private Clinics: New Poll
Nearly Three in Four Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Instead of Private Clinics: New Poll

Business Wire

timean hour ago

  • Business Wire

Nearly Three in Four Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Instead of Private Clinics: New Poll

OTTAWA, Ontario--(BUSINESS WIRE)--Seventy-three per cent of Ontarians believe the government should prioritize spending on public hospitals rather than private clinics, in a poll conducted following the recent budget announcement of $280 million being shunted to private, for-profit clinics. Eighty-four per cent also said they believe public hospitals are understaffed. The Nanos Poll was conducted between May 27 and June 1, surveying 1,017 Ontarians over the age of 18. The poll was commissioned by CUPE's Ontario Council of Hospital Unions (OCHU-CUPE), which released a supplementary report on the ongoing privatization of hospital services. 'This poll shows there is overwhelming opposition to this government's plans to privatize hospital surgeries,' said Michael Hurley, president of OCHU-CUPE, which represents 50,000 hospital and long-term care staff. 'The public understands that spending on private, for-profit clinics and agencies is much more expensive, comes with poorer outcomes and duplicates infrastructure and administration. The vast majority wants our resources allocated to public health care.' While the government expands funding to for-profit clinics, over four in five Ontarians (84%) believe there is not enough staff in public hospitals – including 82 per cent of Ontario PC supporters. In the recent budget health care funding increased two per cent, well below the annual health care inflation of 5.2 per cent, noted the union. After significant privatization of cataract surgeries, the government plans to expand private, for-profit delivery of other procedures including knee and hip replacements as well as diagnostics. In 2023, Premier Doug Ford suggested that up to 50 per cent of surgeries could be performed outside of hospitals. 'This is startling given that for-profit surgeries in Ontario are twice as expensive as those performed in public hospitals,' said Hurley. The OCHU-CUPE report highlights the findings of a 2024 Canadian Medical Association Journal study showing that privatization of cataract operations resulted in surgical rates increasing by 22 per cent for the wealthiest Ontarians while declining for everyone else. Access to surgeries for the poorest people in Ontario declined nine per cent. The study noted that hospitals provided equal access to care. At the media conference, the union showed a visual representation of this inequality through a map of Ottawa's neighbourhoods, colour-coded by socioeconomic status. 'People can't afford to pay thousands of dollars for health care,' Hurley said. 'The great majority of Ontarians reject this expensive privatization that bakes in inequalities and greatly reduces access.' The Ontario Health Coalition has documented hundreds of cases of private, for-profit clinics billing patients for medically necessary services – which is illegal – and add-on services that patients felt compelled to purchase. Sixty-seven per cent of respondents to the Nanos poll said it was unacceptable for private clinics to charge people for medically necessary services. The union expressed concerns about the acceleration of privatization, citing the CMAJ study's findings showing that since expansion of public funding for cataract surgeries in Ontario, 22.5 per cent of these procedures were performed in private clinics. Summary of survey results: 72% agree with the CMAJ study results that privatization will negatively impact access to care for the poorest people 67% say it's unacceptable for private clinics to charge patients for medically necessary services 73% say government must prioritize spending on public health care, not private clinics 84% say there's not enough staff in public hospitals :gv/cope491

Enhanced Genomics Appoints Dietrich Stephan, Ph.D. as Chair of the Board to Lead Ambitious Growth Strategy
Enhanced Genomics Appoints Dietrich Stephan, Ph.D. as Chair of the Board to Lead Ambitious Growth Strategy

Yahoo

time2 hours ago

  • Yahoo

Enhanced Genomics Appoints Dietrich Stephan, Ph.D. as Chair of the Board to Lead Ambitious Growth Strategy

Appointment strengthens leadership team to drive strategy focused on harnessing 3D multi-omics to identify high-confidence, high-value therapeutic targets, to accelerate drug discovery CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--Enhanced Genomics ('Enhanced' or 'the Company'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced the appointment of Dietrich Stephan, Ph.D. as Chair of the Board of Directors. In this role, Dr. Stephan will lead the management team in implementing the Company's strategic plans, including driving expansion of its internal target identification pipeline for common diseases, with an initial focus on autoimmune indications, and establishing strategic partnerships to expedite drug discovery, development, and stratification of clinical trial cohorts based on multi-omic signatures. Dr. Stephan is a highly experienced biotechnology industry leader, with technical expertise in high-throughput and translational genomics and a proven track record in scaling, financing, and leading companies. He has held multiple C-level and board roles, overseen successful exits and acquisitions, and played a central role in developing over two dozen private and public biotech companies, several of which went on to achieve billion-dollar valuations. Dr. Stephan has also led world-leading high-throughput genomic infrastructure programs, such as the neuroscience genomics consortium at the U.S. National Institutes of Health (NIH), which have illuminated the genetic drivers of hundreds of diseases and contributed to the development of technologies for identifying genetic variants in both rare and common diseases. Dr. Stephan completed his fellowship at the NIH National Human Genome Research Institute (NHGRI) and holds a Ph.D. in Human Genetics from the University of Pittsburgh, where he received the Legacy Laureate Award, and a in Biology from Carnegie Mellon University. Enhanced Genomics is the only biotechnology company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence therapeutic targets for common diseases. These targets enable first-in-class drug development with blockbuster potential. Using its proprietary 3D multi-omics platform and cell type-specific atlas, Enhanced is connecting genetic variants in 'gene deserts' to disease-driving genes in the most relevant cell types. The Company's unique approach enables the identification of novel disease targets with strong genetic evidence of causality, increasing the probability of success in the pharmaceutical development process. This platform outputs these high confidence targets in a fraction of the time and cost previously possible. "Until today, most of the common disease-associated genomics data generated over the last two decades has not been translated into causal biology. Enhanced Genomics' 3D single cell-type multi-omics platform is uniquely capable of translating these massive amounts of disease-associated data into actionable insights, to enable the rapid identification of novel therapeutic targets with blockbuster potential," said Dietrich Stephan, Ph.D., Chair, Enhanced Genomics. "The Company is also poised to deliver multi-omics signatures that stratify patients for more effective and efficient trials and, together with its target identification capabilities, is unlocking a new era in drug discovery and development for common diseases." Joanna Smart, Investor Director, BGF, added: "We are very pleased to welcome Dr. Stephan as Chair for our portfolio company, Enhanced Genomics. Enhanced's 3D multi-omics platform has the potential to build on decades of genomics research to deliver high-value assets. Multi-omics is the next emerging frontier of the genomics revolution, promising to unlock almost two decades of genomics insights from the global community to benefit those suffering from a wide range of prevalent diseases — and Enhanced is leading the way. Dietrich's expertise in high-throughput genomics, combined with company building experience, will be invaluable as we drive the Company forward through this next phase." View source version on Contacts Media: Katie OdgaardEmail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store